Prior vedolizumab exposure and fibroblast-derived MMP13 are associated with ustekinumab nonresponse in ulcerative colitis - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Association of Previous Vedolizumab Treatment and Fibroblast-Derived MMP13 with Nonresponse to Ustekinumab in Ulcerative Colitis Patients

  • By

  • Yuiko Tsuruta

  • Yoki Furuta

  • Masatoshi Nakashima

  • Cheng Pan

  • Shota Takano

  • Koichi Sakurai

  • Hideki Kitada

  • Kana Omoto

  • Taichi Matsuyama

  • Yoshinari Sakai

  • Suguru Chiyonaga

  • Kotaro Fukubayashi

  • Takashi Shono

  • Masakuni Tateyama

  • Kotaro Waki

  • Munenori Honda

  • Kenshi Matsuno

  • Akira Yamasaki

  • Hideaki Miyamoto

  • Ryosuke Gushima

  • Takehisa Watanabe

  • Katsuya Nagaoka

  • Hideaki Naoe

  • Yoshihiro Komohara

  • Yasuhito Tanaka

  • September 28, 2026

Share

Clinical Scorecard: Association of Previous Vedolizumab Treatment and Fibroblast-Derived MMP13 with Nonresponse to Ustekinumab in Ulcerative Colitis Patients

At a Glance

CategoryDetail
ConditionUlcerative Colitis
Key MechanismsInfluence of previous vedolizumab treatment on ustekinumab response
Target PopulationPatients with moderate-to-severe ulcerative colitis
Care SettingMulticenter, observational study

Key Highlights

  • Ustekinumab shows efficacy in moderate-to-severe UC.
  • Previous vedolizumab treatment may affect response to ustekinumab.
  • Study involved patients aged 14–84 years with UC.
  • Clinical evaluations occurred at 2, 6, and 12 months post-initiation.
  • Primary outcomes included clinical response and remission.

Guideline-Based Recommendations

Diagnosis

  • Diagnosis of UC based on Japanese Ministry of Health, Labour and Welfare criteria.

Management

  • Induction with intravenous ustekinumab followed by subcutaneous maintenance.

Monitoring & Follow-up

  • Clinical evaluations at 2, 6, and 12 months after initiation.

Risks

  • Consideration of previous treatment exposure when assessing response.

Patient & Prescribing Data

Patients with UC who have received at least one dose of ustekinumab.

Real-world evidence indicates variability in response based on previous therapies.

Clinical Best Practices

  • Monitor for clinical response and remission at specified intervals.
  • Evaluate previous treatment history when initiating ustekinumab.

Related Resources & Content

Original Source(s)

Prior vedolizumab exposure and fibroblast-derived MMP13 are associated with ustekinumab nonresponse in ulcerative colitis

  • by Yuiko Tsuruta, Yoki Furuta, Masatoshi Nakashima, Cheng Pan, Shota Takano, Koichi Sakurai, Hideki Kitada, Kana Omoto, Taichi Matsuyama, Yoshinari Sakai, Suguru Chiyonaga, Kotaro Fukubayashi, Takashi Shono, Masakuni Tateyama, Kotaro Waki, Munenori Honda, Kenshi Matsuno, Akira Yamasaki, Hideaki Miyamoto, Ryosuke Gushima, Takehisa Watanabe, Katsuya Nagaoka, Hideaki Naoe, Yoshihiro Komohara, Yasuhito Tanaka

  • September 28, 2026

Related Content

5.0 T versus 1.5 T and 3.0 T upper abdominal MRI: a prospective two‑cohort study of image quality and diagnostic confidence

Long-term outcomes in recurrent diverticulitis: a systematic review of treatment strategies and recurrence rates

Toward a Rational Use of Probiotics in Very Preterm Infants